header logo image


Page 1,079«..1020..1,0781,0791,0801,081..1,0901,100..»

The Minneapolis Medical Research Foundation Selects Goodwin … – PR Newswire (press release)

March 21st, 2017 1:46 am

"For over 15 years, Goodwin Biotechnology has been one of the pioneers in providing development services and GMP manufacturing of a broad portfolio of Antibody:Drug Conjugate (ADC) and Protein:Drug Conjugate (PDC) projects, including cytotoxic ADCs, Radio-Immunoconjugates, Antibody:Peptide Conjugates, Antibody:Dye Conjugates, PEGylated proteins, and other bioconjugates including Biobetters," said Muctarr Sesay, Ph.D., Chief Scientific Officer at Goodwin Biotechnology. "Our experience in Bioconjugation has resulted in several patents and publications, as well as proprietary processes that enable us to help our clients overcome some significant challenges in developing their next generation of bioconjugates. When including our experience in manufacturing vaccines for use in early- and late-stage clinical trials, we found the Minneapolis Medical Research Foundation project to be highly intriguing."

"This is not an unusual approach for us when we initiate a project because we collaborate with many of our clients in the early stages of proof of concept/development by empirically recommending the appropriate processes to create a viable ADC or PDC candidate," Dr. Sesay continued. "We then blend that with a solutions-oriented approach to help our clients overcome significant challenges to ensure that the process for their candidate is robust, compliant, economical, and scalable."

"We are proud to help advance the treatment for this growing public health concern because we're confident in the expertise that our highly skilled scientists have developed in the areas of ADCs and PDCs, based on the successful work that we have done with over 400 client projects over the last 24 plus years," said Karl Pinto, Chief Executive Officer at Goodwin Biotechnology, Inc. "Our Bioconjugation capabilities complement our experience in successfully developing and manufacturing monoclonal antibodies, recombinant proteins, and vaccines through mammalian cell culture expression systems. So, as part of our Single Source Solution, Goodwin is uniquely qualified to partner with our clients to meet their needs by developing customized and flexible approaches for manufacturing antibodies and recombinant proteins, for example, and / or design the appropriate conjugation activities to cost effectively deliver their product candidates on time."

About the Minneapolis Medical Research Foundation

The Minneapolis Medical Research Foundation (MMRF) is a subsidiary of Hennepin Healthcare System, Inc., and operates as the research arm of Hennepin County Medical Center, an acute care research and teaching hospital in Minneapolis. MMRF is one of the largest nonprofit medical research organizations in Minnesota and consistently ranks in the top 10 percent of all institutions receiving research funding from the National Institutes of Health. To learn more, visit mmrf.org.

About Goodwin Biotechnology, Inc.

Goodwin Biotechnology is a uniquely qualified CDMO that offers a Single Source Solution for our clients from cell line development (through our strategic partner), exploratory proof of concept projects through process development and cGMP contract manufacturing of monoclonal antibodies, recombinant proteins, vaccines, and Biologic Drug Conjugates including Antibody:Drug Conjugates (ADCs) for early and late stage clinical trials. By working with Goodwin Biotechnology, clients can enhance the value of their product candidates with clear development and manufacturing strategies, as well as a road map to meet the appropriate quality requirements from the milligram and gram range to kilogram quantities as the product candidates move along the clinical development pathway in a cost-effective, timely, and cGMP compliant manner to enhance patients' lives. With over 20 years of experience as an independent integrated contract manufacturer, Goodwin Biotechnology has worked as a strategic partner with numerous companies of all sizes from small university spin-offs to major research institutes, government agencies and large, established and multi-national biopharmaceutical companies. Based on the impressive track record, Goodwin Biotechnology has been awarded Frost & Sullivan's Customer Value and Leadership Award for Best Practices in Mammalian Contract Manufacturing in 2014.In addition, Goodwin Biotechnology was awarded 'Best in Sector: Biopharmaceutical Contract Development & Manufacturing' at Acquisition International magazine's 2015 Sector Performance Awards. Most recently, Goodwin Biotechnology received Global Health & Pharma's award for Best for BioProcess Development & cGMP Manufacturing in 2016, and Best in Mammalian Cell Culture Process Development & cGMP Manufacturing 2017. Click here to view the press releases!Additional information may be found at http://www.GoodwinBio.com.

Funding for this study was supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number U01DA038876. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information, please contact:

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/the-minneapolis-medical-research-foundation-selects-goodwin-biotechnology-to-help-develop-and-manufacture-two-vaccines-to-treat-opioid-addiction-300426025.html

SOURCE Goodwin Biotechnology, Inc.

http://www.goodwinbio.com

Original post:
The Minneapolis Medical Research Foundation Selects Goodwin ... - PR Newswire (press release)

Read More...

‘Synthetic’ cartilage is now an option for big-toe arthritis sufferers – Detroit Free Press

March 21st, 2017 1:45 am

The Cartiva cartilage works like a bumper over the joints and is inserted into the base of the big-toe through a drilled hole. Courtesy of Cartiva

Karen Schumman, 51, of Chesterfield Township had a Cartiva implant put into her big toe on the left foot. She is photographed on March 17, 2017 at her home.(Photo: Mandi Wright, Detroit Free Press)Buy Photo

Orthopedic surgeon Dr. Matthew Brewster had long sought abetter treatment option for his younger,still-active patients suffering from arthritic joint pain in their big toe.

The gold standard for moderate to severe big-toe arthritis a fusion of the bones could relieve their painbut permanently rob them of mobility in the toe, limiting their ability to partake in athletic activities such as jogging and, for women, wearing heels.

"I didn't like fusing 55-year-old women'stoes that want to run and wear heels," said Brewster, who practices at Associated Orthopedists of Detroit and is affiliated with Beaumont Hospital in Grosse Pointe.

So when the U.S. Food and Drug Administrationlast July approved the first synthetic cartilage-like implant as a treatmentforbig-toe arthritis, he signed up. Brewster performed his firstprocedure with the Cartiva implant that month, helping a 62-year-old Clinton Township woman regain the ability to wear shoes without pain and even go running.

Read more:

Boy born without limbs in line for MSU-designed prosthetic

Study: Parenthood can boost your longevity

She became only the second U.S. patient to receivethe implant, which has been available in Europe for more than a decade. The first procedure was in Rochester, N.Y.

Brewster, the procedure's second U.S. doctor,has since successfully treated 13 patients with theimplant. All of them were relieved of their painand kept about half of their pre-arthritis joint mobility, he said.

Although the implant material is onlycurrently approved in the U.S. for the bigtoe,it has beensuccessfully usedto treatarthritic thumbs and knees in Canadaand Europe and offers hope for the millions ofarthritis sufferers who wish to remainactive and avoid jointreplacementsthat stealtheir mobility and require extensive surgeriesonce the deviceswear out.

An estimated 2.7 million middle-age people in the country right now have big-toe arthritis.

Brewster's patients'healthinsuranceagreed to cover the Cartiva implantand procedure costs, which aresaid to be slightly higher than a standard bone fusion.

"When he approached me with this, it sounded too good to be trueit's not," saidKaren Schumann, 51of Chesterfield Township,Brewster's most recent patient, whosebig-toe procedure was Feb. 22.

Dr. Matthew Brewster who practices at Associated Orthopedists of Detroit in St. Clair Shores and is affiliated with Beaumont Hospital, Grosse Pointe. He is the second doctor in the U.S. to do Cartiva implants.(Photo: Henry Ford Health System)

In an interview last week, Schumann recalled how her left toe had beenin increasingpainfor nearly 10 years and that she could no longerbend it. Now more than three weeks after the operation, her pain level is "zero," and sheonce again can go on long walks for exercise and go up and down stairs.

She hopes to have the same procedure done later this year on her right foot.

"I am so glad I had it done. You never realize how much you use the big toe until it hurts," Schumann said.

Headquartered outside Atlanta with 25 employees, Cartiva developed its Synthetic Cartilage Implant through research that originated out ofGeorgia Tech. The device is made of polyvinyl alcohol hydrogel, the same material as contact lenses, but is much thicker and the result ofapatented process that makes thematerial incredibly toughyet with a water content comparable to healthy cartilage. Eachimplantis expected to last many years, although the materialis still too new to makeprecise estimates.

Cartilage is a smooth,connective tissue that has a limited ability to repair itself if damaged. Researchers have been tryingfor decades to find a way to replace it. Degenerative arthritis occurs when cartilage gets worn away and bones then rubagainst each other.

"Synthetic cartilage or injectable cartilage or some type of implantable cartilage is definitely the Holy Grail of orthopedics," said Dr. Todd Irwin, a foot and ankle orthopedic surgeon at the University of Michigan Health Systemwho has done two Cartiva implant procedures.

"I think this is very promising," Irwin said, but added,"I think calling it synthetic cartilage is personally a little bit of a stretch. To me, functionally it's more of a bumper" between the bones.

Cartiva first introduced its hydrogel implantin Europe in 2002. But gaining FDA approval entailed more clinical trials and didn'thappen until last July.

Karen Schumman, 51, of Chesterfield Township had a Cartiva implant put into her big toe on the left foot. She is photographed on March 17, 2017 at her home.(Photo: Mandi Wright, Detroit Free Press)

Big-toe arthritis, known as hallux rigidus, isthe most common arthritic condition in the foot and said to affect 1 in 40 people older than 50, or roughly 2.7 million people in the U.S. Doctors say the problem can arise fromgenetics, past injuries orrepeated stress from work occupations such as flooring installation.

Yet only about 100,000 Americans each year the majority of them female getsurgical treatment for the condition, through fusions or typically metal joint implants. Those with less severe arthritis can find relief through a cheilectomy, which involves cleaning out the joint and removing bone spurs, althoughthat procedure currently rules out getting a Cartiva implant later on.

Doctors say the biggest problems with traditional implants for the big toe are therelatively high complication rates and how they often don't last beyond seven years.

The Cartiva cartilageworks like a bumper over the joints and is inserted into the base of the big-toe through a drilled hole.

Brewster said the procedure is relatively simple and takes him about 25 minutes. He considers it easier to perform than a traditional joint fusion of the toe, whichtakesmore than an hourand involves scraping out cartilage, packing in a cadaver bone graft,then screwing two bones together with a metal plate.

Patients are sedatedduring the procedure and afterward canactuallywalk out of the clinic. For two weeks theyare asked to wear a post-operative shoe, like a hard sandal. After that they can return to regularactivities.

A smallpeer-reviewed study of 27 Cartiva patients in Canada and the United Kingdom foundthat five years after theimplant,toe functionality had improved significantly in nearly everyone compared to before theirprocedure, the pain was significantly reduced and the synthetic cartilage was in good shape.

A full96% of the patients said they would undergo the procedure again.

Rosalynn Demers, 62, of Clinton Township was the first Michigan patient to receive the Cartiva implant.She had been enduring progressively worse big-toe pain for about a year and could nolonger wear most shoes because ofpain.

The Cartiva Synthetic Cartilage Implant was approved by the FDA in July 2016 to treat big-toe arthritis. (Photo: Cartiva)

"I thought it was a bunion, but it was arthritis. It was a gradual thing and then (the pain) just became ridiculous," she said. "I thought I as going to give all my shoes away, thinking that I'd never fit into them again."

She had planned to get a fusion, even thoughshe knew the procedurewould bringan end to her running hobby.Then she learned about the new FDA-approved synthetic cartilage option from her husband, Dr. Mike Demers, an orthopedic surgeon who is a colleague of Brewster's.

The Cartiva Synthetic Cartilage Implant was approved by the FDA in July 2016 to treat big-toe arthritis. (Photo: Cartiva)

In late July,Demers became the second person in the country to get theprocedure. Itwas asuccess. Not only is sheback to wearing almost all of hershoes, but she returned to running and evenraced in the Detroit Turkey Trot5K inNovember.

"I couldn't believe I ran the whole thing," she said. "It wasn't fast, but I ran it. So I thought that was pretty incredible."

Schumann, theChesterfield Township woman who just had theprocedure,recalled howBrewster demonstrated the new pain-free range of motion in her toe during a check-up appointment. Prior tothe operation, asudden movement like that would have causedsearing pain.

"All of the sudden, he bends my toe all the way down and I'm like, 'What!'" Schumann said. "He says, 'Does that hurt?' and I go, 'No you just scared me.' My toe has not been bent like that in years."

The list price of each Cartiva implant is $4,500, although hospitals can get a discount from the company.

A Beaumont representative said the Grosse Pointe hospital'stotalchargesfor the Cartiva procedure average$15,000 to $17,000. Insurance companiesthen typically pay around33% of the charges, or about $5,000, leaving the hospital to writeoff the remaining balance. Thosecharges donot include the surgeons fee, which is billed separately to insurance.

Nationwide, the averagebig toe-fusion is billed at $10,000 to $11,000 before insurance not including the surgeon's bill, according to James Laskaris, an emerging technologies senior analyst at MD Buyline, a Dallas-based firmthat provides clinical and financial information to hospitals. The surgeon istypically a $3,000 to $4,000 separatecharge, Laskaris said.

In addition tobig toes, doctors in Europe and Canada have had success using Cartiva implants to treat arthritic thumbs and knees.

Dr. Philip Sauve in the U.K. said he has treated 12 patients with thumb arthritis with a Cartiva implant. All had good results, he said.

"Thepain is reducing, their grip strength is increasingand so their function is improving," Sauvesaid in a phone interview. "So for that group who maybe is still working and still very active, I think it's a really good option."

Contact JC Reindl: 313-222-6631 or jcreindl@freepress.com. Follow him on Twitter@JCReindl.

Read or Share this story: http://on.freep.com/2numr43

See more here:
'Synthetic' cartilage is now an option for big-toe arthritis sufferers - Detroit Free Press

Read More...

Arthritis can’t stop art – Kankakee Daily Journal

March 21st, 2017 1:45 am

Kankakee Daily Journal
Arthritis can't stop art
Kankakee Daily Journal
Linda Randall-Powles had stage 4 arthritis, a disease that would inhibit many from being able to paint. Nonetheless, she never let it get in her way. "I have never known anyone so seriously afflicted with arthritis as Linda, yet she never complained ...

Read more here:
Arthritis can't stop art - Kankakee Daily Journal

Read More...

Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula – The Missoulian

March 20th, 2017 12:48 am

The Resource Center at Missoula Aging Services (MAS) is partnering with the MSU Extension Office and others to offer a six-week course for older adults with diabetes or pre-diabetes. The Diabetes Empowerment Education Program (DEEP) is available free to Medicare participants and their caregivers.

Classes will help people with diabetes learn how to take charge of their health and get control of the disease. While they are designed for older adults with Medicare, anyone with diabetes or pre-diabetes is welcome to attend. Courses will be held Tuesdays from 10 to 11:30 a.m., beginning Tuesday, March 28, and continuing through May 2, at the Missoula County Extension Office, 2825 Santa Fe Court.

Please call MAS at 406-728-7682 for more information or to register, or go to deepclasses.eventbrite.com to register online. Additional partners include Mountain-Pacific Quality Health, Everyone with Diabetes Counts (EDC), and the Montana Geriatric Education Center.

The YWCA Missoula invites you to LUNAFEST, a local event hosted by the GUTS! (Girls using their strengths) Program. GUTS! partners with LUNAFEST, an exciting national film festival featuring short films by, for and about women, to highlight the capacity, strength and beauty of women in film and young women of Missoula. This event will raise funds for our Summer Outdoor Adventure Trips and a smaller percentage for the Breast Cancer Fund. LUNAFEST will be held on Wednesday, April 19, at the Wilma Theater in downtown Missoula. Doors open for our silent auction at 6 p.m. and the show starts at 7 p.m. Tickets are $15 in advance, $18 day of show.

Child Care Resources training: Spring Conference is set for Saturday, April 1. How do we create rich environments that meet early childhood standards and allow children and their teachers to flourish?

As an active participant, sharing photos and discussing and brainstorming environmental successes and challenges in your child care program. Youll also create a design for one learning center that you can immediately begin to create in your program.

This conference will be held from 9 a.m. to 4 p.m. on Saturday, April, 1. This training is $25, and is worth six training hours.

Application workshops for anyone interested in applying to build a home in partnership with Habitat for Humanity of Missoula will be held Sunday, April 2, at 2 p.m. and Wednesday, April 5, at 7 p.m.

Workshops will be held in the conference room at the YWCA located at 1130 West Broadway.

No child care will be available at either meeting.

Applications will be available at the meetings. Access to our applications on our website or to pick up at our office will be available on Tuesday, April 4. Completed applications must be submitted by 5 p.m. on Friday, April 21.

Call 406-549-8210 for more information.

To help older adultswho want to get better control of their diabetes, Mountain-Pacific Quality Health, the Medicare Quality Innovation Network-Quality Improvement Organization (QIN-QIO) for Montana, Ag Worker Health & Services and the Montana Geriatric Education Center are partnering together to offer a series of six, free diabetes classes. These classes provide fun, informative and interactive ways to help people with diabetes or pre-diabetes (high blood sugar)

The classes support, not replace, professional diabetes self-management education. The classes are designed for people age 65 and older. Ag Worker Health & Services will make future announcements about any classes or events for those younger than 65.

The series kicks off Monday, April 17, from 5:30 to 6:30 p.m., at Ag Worker Health and Services at 9801 Valley Grove Drive #D, which is about a half mile north of Lolo on Highway 93. Classes will then meet every Monday through May 22. Anyone interested in attending theses classes can register by calling 406-273-4633.

Humanities Montana awarded a $900 grant to The Montana Racial Equity Project to support the Native American Race Relations and Healing Symposium. The day-long event will feature two panel discussions lead by authors, historians, language preservationists, and experts including John Robinson and Sterling HolyWhiteMountain. The first panel will focus on tribal sovereignty and the second will explore current issues facing the Native American population. The event will take place on Saturday, April 1, from 10 a.m. to 3 p.m., at the Native American Studies Building at the University of Montana.

Humanities Montana awarded a $1,000 grant to the Wedsworth Memorial Library to fund a monthly book discussion. Dr. Penny Hughes-Briant will host eight discussions from August 2017 to May 2018. All events will be held at the Wedsworth Memorial Library in Cascade.

Humanities Montana awarded a $1,000 grant to Columbus High School to fund the Yellowstone National Park Inquiry Project. Students will research and build projects on the impacts that visitors have on Yellowstone National Parks animals, ecosystem, environment, and cultural values.

Humanities Montana is the states independent, nonprofit state affiliate of the National Endowment for the Humanities.

View original post here:
Nonprofit roundup: Courses on managing diabetes begin March 28 in Missoula - The Missoulian

Read More...

Colorado Springs family adapts to reality of Type 1 diabetes as, one after one, children are diagnosed – Colorado Springs Gazette

March 20th, 2017 12:48 am

Siblings Melanie, McGuire, Emily and Ashley, all of whom have type 1 diabetes, goof off as parents Julie and Bubba Hayes watch at their home on Wednesday, February 1, 2017. Julie and Bubba Hayes have four out of five children with type 1 diabetes. Photo by Stacie Scott, The Gazette

It was a cold, wet California winter and Julie Hayes, her husband, Bubba, and their five kids all were laid low by a nasty stomach virus. When a week went by and 3-year-old Ashley hadn't rallied like her twin sister and the rest of the family, Hayes started to worry. The toddler was wetting the bed, which she hadn't done in at least a year, and though she ate nonstop, never seemed to get full. She'd sleep half the day and wake exhausted.

Hayes explained the examples of uncharacteristic behavior to the emergency room doctor, who peered into Ashley's eyes, had her stick out her tongue, and asked if diabetes ran in the family.

"I looked at him and said, 'I don't even know what diabetes is," Hayes said.

That, and life as she knew it, was about to change.

Over the following eight years, three more of her children would be diagnosed with Type 1 diabetes, a scenario that - even among families with a history of the disease - defies medical odds and, in many ways, illustrates the mysteries at the heart of genetic dynamics.

"I can tell you that the great majority of families have only one patient. Maybe 10 percent have two patients (and) there's just a handful of families with more than two," said Dr. Robert Slover, the Hayeses' physician and director of pediatrics at the Barbara Davis Center for Diabetes at the University of Colorado Anschutz Medical Campus in Aurora. "That is an extremely unusual situation to have it happen to four children in a family."

For people with Type 1, formerly mislabeled "juvenile" diabetes, something - often a virus - kicks off a faulty immune system response that causes the body to attack the cells that produce the insulin needed to break down dietary carbohydrates and regulate blood sugar. As those cells die, the internal insulin machine becomes more and more compromised and eventually ceases to function.

"We are not exactly sure why the autoimmune process gets started, but the result is clear: The body turns on its own immune system to fight some common virus or agent and that destruction spills over," said Slover, whose center is home to one of the world's larger and more preeminent programs specializing in Type 1 diabetes research and care. "When that remaining group of cells shuts down, you go from maybe having enough (insulin) to be OK to not enough and having all the symptoms of diabetes."

A complex disease

As researchers stalk a cure and technological revolutions make management easier for those with the disease, the "why" of diabetes often remains elusive, the outcome of a complex equation and moving parts - genetic legacy and environmental influences - that, for now, can be answered only in theory.

"We know that people inherit a predisposition to the disease, then something in the environment triggers it ... but most who are at risk do not get diabetes," Slover said.

In people with a genetic risk of autoimmune ailments, research has identified a handful of factors that seem to affect the odds of them developing the disease, which emerges more often in winter and is more common in places with cold climates. Early diet may also play a role, as the disease is less common in people who were breastfed and who began eating solid foods at later ages. And though the evidence is more anecdotal than empirical, the increase in autoimmune diseases may have something to do with First World lifestyles, Slover said.

"In a less-sanitary America, there was a lot more exposure to animals, to foreign proteins and diseases, and people seemed to have almost a natural immunization," he said. "Statistics show that poorer nations that are less sanitary have a lower rate of developing Type 1 and other autoimmune diseases."

In the Hayeses' case, though, theories and statistics fall short.

"If a couple with the same genes had the same number of children, the odds are that most of the children wouldn't get all those same genes" that lead to the development of Type 1, Slover said. "The logic is backward - because it happened, it follows that the children must have inherited the predisposition."

Rising numbers

One thing Slover can say for certain is diabetes, and autoimmune diseases in general, are on the rise across the developed world. Over the past two decades, Type 1 diagnoses have increased at an annual rate of between 3 and 4 percent.

"Last year, we saw 450 newly diagnosed children. Ten years ago, it would have been more common to see 250," Slover said, adding that he's seen the greatest increase among toddlers and those over age 20, who today represent almost half of patients. "In pediatric populations, we used to talk about something of a peak in early adolescence - ages 7 to 13 - but these days I don't think that stands up."

Before insulin was discovered in 1921, diabetes had a grim prognosis. Most sufferers died in infancy or soon after manifesting symptoms; for those who didn't, a no-carb, starvation-level diet and rigorous exercise might buy an extra year. Today, pharmaceutical insulin is a miracle drug that allows an estimated 1.25 millions Americans to live out their otherwise natural clocks, so long as they adhere to a strict regimen of blood testing, injections and constant vigilance.

For a "D-mom" of four, it means life at DEFCON 2.

"You have to learn how to use insulin and regulate blood sugar when it's normally something your body does without you even thinking," said Hayes. "It makes you very nervous - can you even take care of your child?'"

On the ground, her and her husband's long-shot "bad collision of genes" is only vague context and background noise.

"Each child, each individual, this is their whole life," she said. "Each time . with each diagnosis . you're devastated all over again."

Telltale signs

A year after Ashley's diagnosis, the Hayes family was still adjusting to the new fulcrum of diabetes when her identical twin, Emily, began to exhibit similar symptoms.

She "just had this look," said Julie Hayes, who told her daughter she'd like to poke her finger, "like Ashley has to."

That evening, she called a family meeting to break the news. Ashley, who knew what it was like to have diabetes, immediately burst into tears; Emily's reaction, however, struck her mother as "kind of comical."

She was "just laughing and smiling and jumping up and down. Like, she got to be like her sister now," said Hayes, whose family moved to Colorado Springs in 2006. "It's terrible for them both to have it, but they have each other. It gave them a teammate and partner in diabetes, so it kind of seemed like it was meant to be."

The reception wasn't so enthusiastic when daughter Melanie was diagnosed, at age 11, after Hayes noticed telltale signs, such as extreme thirst, that her daughter's internal glucose regulation system was shutting down.

By the time McGuire was 14 and came downstairs complaining of feeling unwell and worried about his blood sugar, the hallmarks and lingo of diabetes were household knowledge. At the time, though, Mom chalked the complaint up to malingering. There was no way she had another child with Type 1.

"I was like, 'OK, whatever. Do your test, but as soon as you're done you're going to school,'" she said.

Constant vigilance

As parents to one, then two, then four children with Type 1 diabetes, Julie and Bubba Hayes learned to make do on a patchwork of sleep. Julie spent nights haunting the halls with a glass of juice and glucose monitor, poking fingers and checking blood sugar as her children slept. The kids got used to it; sometimes, they barely woke.

By the time Ashley and Emily were in their early teens and making a name for themselves on the bicycle motocross circuit, their mother thought everyone had a "pretty good handle" on diabetes. The twins, Melanie and McGuire all were on the insulin pump and had proven good stewards of their numbers. If they were feeling low at night, when the risk of blood sugar bottoming out is greatest, they'd wake up Mom so she could pour them some juice and tuck them back into bed.

In the fall of 2015, though, after a series of nights during which her blood sugar dropped to dangerous levels, daughter Emily had a hypoglycemic seizure.

"She was seizing and blue. I'd never experienced anything so scary in my whole life. Ashley was there, literally screaming her sister's name," said Hayes, who called for an ambulance to administer the life-saving injection of Glucagon, a substance that works quickly to raise blood sugar levels.

Hayes felt the old panic of uncertainty about her role, as parent - and sentry.

"It's a reality that people do die from this disease, from low blood sugar, and it happens mostly when they're sleeping," Hayes said. "Diabetes is so much scarier than we ever thought it was."

A better routine

Adolescence can be especially tough when compounded with the challenges of diabetes.

"Typically, worldwide, diabetes is hardest in the teenage years, not because teens are uncooperative but because they're growing and dealing with hormonal changes and that can be difficult," Slover said.

Today, all the Hayes children are teens except the oldest, 21-year-old Aubrey, who does not have diabetes (but, said Slover, remains at increased risk). New innovations play a vital part in managing day-to-day health.

After Emily's seizure, all began using a Dexcom continuous glucose monitoring system that keeps track of numbers using a subdermal sensor the size of two strands of hair and a 2-inch transmitter that can be worn for up to a week. In fact, the teens participated in trial research that helped usher the technology to federal approval late last year.

"Julie's incredible, and her interest in helping her own children - and helping us get a handle on that (diabetes in adolescence) - has been wonderful," said Slover, who continues to meet quarterly with the teens. "We owe a big debt of gratitude to all our patients helping us with that research."

With the new technology, rather than multiple finger-sticks each day the Hayes children need only test their blood sugar in the morning and at night, before bed, to calibrate the device. Results are transmitted to an iPhone app that issues alerts if blood sugar begins to move into critical ranges, low or high.

"You get a lot of alarms going off if it hits that point," Bubba Hayes said.

Not only does the technology help the Hayeses sleep more seamlessly, a feature allowing long-term tracking of glucose numbers has encouraged the children to improve their hemoglobin A1C, a measurement of blood sugar levels over a period of time.

The new setup expands the safety net for health maintenance into the digital realm. Users can chose up to five followers who also receive live data from their transmitter via a private social media app.

Seventeen-year-old Melanie Hayes' Dexcom network includes her mother, father, big sister and two best friends. "If I'm even slightly high, I start getting texts," she said. "My friend David will send me a text with an emoji for up or down. If I'm down, he'll say 'Hey, drink a juice.' That's really helpful."

-

Contact Stephanie Earls: 636-0364

Twitter: @earls_stephanie

Follow this link:
Colorado Springs family adapts to reality of Type 1 diabetes as, one after one, children are diagnosed - Colorado Springs Gazette

Read More...

Wins for Kansas: Juvenile Diabetes Research Foundation – KAKE

March 20th, 2017 12:48 am

WICHITA, Kan. (KAKE) -

Type 1diabetes is an autoimmune disease that can strike suddenly. The Juvenile Diabetes Research Foundation is working toward finding a cure, to help boys like Josh Dinkle.

Dinkle looked like any other little boy. But by age 13, he started displaying symptoms thatturned out to be type 1diabetes.

"It's so much more than people realize," Dinkle's mother Kim said.

Everything he drinks, eats and even emotescan cause his blood levels to crash.Like any good parent, Kim Dinkle monitorsher son's blood levels. She calls it a full-time job.

"You can't have a day off, a moment off. You check every moment what's going on with your blood sugar," she explained.

Each year, 40,000 Americans are diagnosed with type 1. The national non-profit group JDRFis on the front lines in the battle, and itsbig fundraiser is the "One Walk" event. The Wichita walk draws thousands, and raiseseven more.

Those donations translate into breakthroughs, according to organizerDe White."There was a time type 1was a death sentence. Now we are looking for our children to have a life sentence," White said.

With that in mind, KAKE'spartners at Wins for Kansas want to help. DeVaughn James Injury Lawyers provided a $500 grant, "to turn type 1e into type none."

If you'd like to register for the One Walk on Saturday, April 1, it's not too late. Click on this link for details.

Continue reading here:
Wins for Kansas: Juvenile Diabetes Research Foundation - KAKE

Read More...

The Affordable Care Act Helped With Type 2 Diabetes Treatments: One Woman’s Story – Reno Public Radio

March 20th, 2017 12:48 am

The nation is embroiled in the debate over the Affordable Care Act. The

Congressional Budget Office estimates that the GOP health bill could put 24 million Americans at risk of losing insurance. That has many local patients and doctors worried. Because of the ACA, more people were able to get health insurance and even access to life-saving treatments. One Reno woman shares her story with our reporter Anh Gray.

I meet Angela Siegfried at the Community Health Alliance Center For Complex Care on Wells Avenue in Reno. Its where she goes for health care. Siegfried has big, brown eyes and is full of optimism. Thats despite having to get around with the aid of an oxygen tank due to complications from Type 2 diabetes. These days Siegfried says shes grateful to have the oxygen. Before the Affordable Care Act, she was uninsured.

I would just get really sick and end up in the hospitals, emergencies, Siegfried explains, theyd keep me, get me a little bit well and send me on my way.

Siegfried says she was a loan officer but became too ill to work and eventually lost her insurance. Now shes receiving treatment at the community health center, which primarily serves low-income people.

Im an out of control diabetic; Im on insulin five times a day, pills, Siegfried says. Im on oxygen COP; Im ready to get a surgery thats called the sleeve so that my health will even be better. I wont be diabetic no more; I wont need oxygen.

Siegfried says her quality of life improved dramatically.

So as long as I have my oxygen, I go with my grandkids; I have three grandkidssix, seven, and eightlittle boys and they go to the park all the time and they wont go without me, Siegfried says about spending time with her grandsons. I get to go to soccer games, I get to go to church all the time. Im not just bedridden.

Oscar Delgado is a spokesman for Community Health Alliance where Siegfried receives her care. He also happens to be a City of Reno councilman.

Preventative care is all about getting ahead of it, right? Trying to make sure the person is taken care of and their health care needs are taken care of now or on the forefront, Delgado says.

In light of the current House Republican proposal to change the Affordable Care Act, Deglgado says hes concerned that some residents could lose access to care and the effect it would have on the community.

The ACA touches everything that we do here in the community one way or another, Delgado explains. In terms of, if peoples health care isnt taken care of, and they feel that they cant be taken of, the governments, the local governments starts to find a way of how they can provide a service.

Delgado says when people lack preventive care, problems persist. This could then trickle down to other areas like increasing the use of emergency care at hospitals, ambulatory care like REMSA, and even to other support services like the fire department.

Chuck Duarte, the CEO of Community Health Alliance, says hes worried that changes to the ACA would be a setback.

If it goes away, the chances are that those uncompensated costs are going to increase, Duarte points out, which means that those costs will shift to employer covered commercial insurance and their premiums will increase. It will affect everybody.

Duarte recalls a less than ideal health care environment prior to the ACA.

Its terrifying for a lot of families to have to face the fact that they may again be uninsured and have to face very large medical bills or not be able to pay for coverage, Duarte says.

Before Obamacare, almost a quarter of Nevadans were uninsuredthe second highest rate in the nation. Now were at about 11 percent.

For patients like Angela Siegfried, the possibility of losing coverage puts her on edge.

I dont ever want to be in this life without insurance. People who dont have insurance, I know what it feels like and its really sad because when youre sick and you cant go to the doctors and you cant get medications, Siegfried explains. Whats going to happen? The only thing, youre going to end up dying, and you probably could have prevented it. Yeah, Im a little nervous about it.

Helping Angela Siegfried get to her medical appointments is her daughter Nadine.

Back when we were without her having insurance, well, I almost lost her several times going to a diabetic coma. It became very serious. And me being an only child, I would have lost my mom, and I would have felt like Im in this world alone.

Siegfried plans to get healthy for her family. Nadine helps wheel her moms oxygen tank toward the medical front desk. Siegfried is eager to get her next medical appointment on the books.

Link:
The Affordable Care Act Helped With Type 2 Diabetes Treatments: One Woman's Story - Reno Public Radio

Read More...

Raising Awareness for Type One Diabetes in Naperville – Naperville Community Television

March 20th, 2017 12:48 am

Posted on March 19, 2017

12-year-old Naperville resident Paige Laurinec was diagnosed with type one diabetes when she was 8-years-old.

Everyday I wake up and I know what I have to do, during the day Ive adapted to carrying a purse with me to hold all my stuff, when lunch comes around I know I have to check and count all my carbs, explained Paige Laurinec.

Its what she and around 200,000 children who are diagnosed with type one diabetes endure everyday as the disease stops their pancreas from creating insulin. That means they need to replace it to maintain their health.

Insulin actually acts to lower your blood sugar it does a lot of different things to allow cells to uptake blood sugar and through multiple different activities it allows us to control our blood sugar, explained Dr. Jim Lengemann, Co-Medical Director of Edward Medical Group.

Local business owner Debbie Kliegl wanted to do her part to raise awareness of the disease and help find a cure. So she hosted a fundraiser donating 30% of all proceeds from Yogurt Beach on March 14 to help kids in our area that suffer from the disease.

We want to connect with our community and make a difference, we want people to understand were here for them, were a business, yeah,but were here to help the community. They help us and we help them, we want to work together, said Kliegl.

While doctors arent sure how long finding a cure may take, mothers of Paige and five-year-old Cayden, who also suffers from the disease, are hopeful more people will become educated about type one and help fund researchfor a cure.

A lot of people just dont know the difference, like oh if you eat too much sugar youll get diabetes, its really not true, especially with type one. I just pray for a cure everyday and I try to educate as much as I can and get involved as much as I can, said Sue Laurinec, Paiges Mom.

I know that were leaps and bounds further then we were years ago so were all hoping that for a cure. I dont know if were ever going to find it but we just choose to support it and hope that Cayden will see a cure in his lifetime, said Amy Nottke, Caydens Mom.

A sweet dream for the future.

Naperville News 17s Alyssa Bochenek reports.

See the article here:
Raising Awareness for Type One Diabetes in Naperville - Naperville Community Television

Read More...

Brit scientists testing ‘groundbreaking’ therapy that could cure … – The Sun

March 20th, 2017 12:45 am

The treatment is aimed at one of the most common causes of blindness in boys and young men

SCIENTISTS seeking a cure for blindness are testing a groundbreaking gene therapy on British patients.

The clinical trial aims to find a treatment for one of the most common causes of blindness in boys and young men.

Alamy

X-linked retinitis pigmentosa, allows the retinal cells to gradually stop working and eventually die, which prevents the eyes from processing light. There is currently no treatment available for sufferers. The trial, which could feature up to 30 patients, follows success by an Oxford

University team in treating those with another form of hereditary blindness, known as choroideremia.

Last Thursday a 29-year-old man with XLRP became the first patient to undergo the gene therapy procedure at Oxford Eye Hospital.

A virus carries corrective DNA into cells at the back of the eye.

For the treatment to work scientists have to reprogramme a gene called RPGR to make it more stable. The instability of that gene in the retina has previously been a major obstacle to finding a way of tackling the condition.

Prof Robert MacLaren, of Oxford University, said: We have spent many years working out how to develop this gene therapy.

Changing the genetic code is always undertaken with great caution, but the new sequence we are using has proven to be highly effective in our laboratory studies.

See more here:
Brit scientists testing 'groundbreaking' therapy that could cure ... - The Sun

Read More...

Doctors warn of ‘sneaky’ condition causing blindness – Starts at 60

March 20th, 2017 12:45 am

Dont miss what is right in front of you.

It is the message being shared as part of the Glaucoma Aware campaign, following World Glaucoma Week last week.

The Glaucoma Aware campaign aims to unearth 150,000 Australians who face preventable blindness and dont know it.

Glaucoma Australia reports more than 300,000 Australians have the condition but only half of those have been diagnosed.

According to the campaigns recent survey results conducted by Edelman Intelligence, around 60% of Australians either havent been tested or dont know if theyve been tested for glaucoma.

This is of great concern to Optometry Australia, which is on a mission to curb preventable eye disease through regular eye examinations.

80% of blindness in Australia is preventable, and with vision loss costing the economy $16.6 billionper year there are many reasons we should be looking after our most precious sense.

Optometry Australias resident optometrist, Luke Arundel said the motivation for getting an eye test often only comes when changes to vision are noted.

In some cases, thats shutting the gate after the horse has bolted. Luke Arundel

Read more: The vegetables that will keep your vision sharp.

Glaucoma is one of the sneaky conditions that can progress undetected without a check-up until significant amounts of vision are irreversibly lost.

Its an invisible, painless disease which affects our side vision, and because it often occurs in one eye first many people do not notice it in the early stages, as their good eye compensates for the vision loss in the other eye. The sad truth is that a lot of Australians are out there undiagnosed right now.

Because its nerve damage, theres no getting it back. But if we pick it up early, we can stop you losing more vision or stop you from going blind, so of course the earlier detection is made the better. More people can be assisted with reading, computer use and day to day tasks than previously, Mr Arundel said.

Read more: Macular degeneration and diet.

Age and family history are the biggest risk factors. According to National Health and Medical Research Council guidelines, glaucoma prevalence is four to ten times higher in people aged 60 years or older, compared to individuals in their 40s.

Relatives of glaucoma patients have a ten-fold increased risk of developing the disease2.

National guidelines encourage every Australian over the age of 50 to get a comprehensive eye examination to test for the early signs of glaucoma.

This video, launched for Glaucoma Week, shows the tragic loss of vision and precious moments which could have been saved by earlier detection.

To find an optometrist in your area visitgoodvisionforlife.com.au.

See original here:
Doctors warn of 'sneaky' condition causing blindness - Starts at 60

Read More...

The Amazing Technology Behind Colour Blindness Glasses – Women Love Tech (press release) (blog)

March 20th, 2017 12:45 am

An estimated 300 million people worldwide are colour blind men are more likely to be colour blind (eight per cent) while only 0.5 per cent of women are affected.

Its more accurate to say that most colour blind people are only partially colour blind, as they can still see colours, but they only see a narrow range of colours.

For decades, there have been glasses that claim to help the colour blind. They typically use a pink or reddish-tinted lens but its no different from looking through a pane of glass thats coloured red or pink.

But now there are colour blind glasses that feature sophisticated technology that has had astounding results.

EnChroma CEO Andy Schmeder told Women Love Tech, in the past, colour blind glasses have not been very effective.

They can help the colour blind do better on colour vision screening tests like the Ishihara test. However, such glasses simply create more contrast in colours because they emphasize one colour at the expense of another. The colour blind arent truly seeing more hues of colour and the glasses distort the colours they already see just fine. Essentially, they are similar to looking through a coloured pane of glass, Schmeder said.

EnChroma has revolutionised the technology behind colour blind glasses by creating a special patent-pending optical technology known as multi-notch filtering.

Red-green colour blindness is caused by an overlap of the green and red cones in the retina of the eye. EnChroma created the multi-notch filtering that removes small slices of light where the red and green cones in the retina overlap the most for the colour blind, Schmeder said. This re-establishes a more accurate ratio of light entering the three photopigments in the eye so the colour blind enjoy a more normal spectral response. The result is colour blind people experience enhanced colour, an improved ability to differentiate hues of colours, and better depth and detail perception.

The EnChroma glasses were researched through three US National Institute of Health (NIH) research grants and 10 years of R&D and clinical studies using scientific colour vision tests such as the D-15.

The glasses enhance the vibrancy and saturation of certain colours and improve colour discrimination, depth and detail perception without distorting the colours the colour blind already see well.

We hear from parents who tell us their child is now more confident in school because they can better see the colours in a social studies map or tell the difference when their teacher writes in red, green or purple marker on the board, Schmeder said.

Its amazing to see artists who use colour every day gain a better understanding or appreciation of the colours they routinely use. Some people see the red hair or green eye colour of a loved one or are simply transfixed that the grass in the yard of the home theyve been living in all their life has multiple hues of green in it instead of just one monochromatic dull green colour.

You can take the online colour blindness testto learn what type of red-green colour blindness you have and to learn the odds of EnChroma glasses helping you.

Go here to see the original:
The Amazing Technology Behind Colour Blindness Glasses - Women Love Tech (press release) (blog)

Read More...

Biotechnology 2017 | Biotechnology Congress | Canada …

March 20th, 2017 12:44 am

Allied Academies cordially invites all the participants across the globe from leading universities, clinical research institutions, diagnostic companies and all interested to share their research experiences in the Annual Biotechnology Congress during August 17-18, 2017 in Toronto, Canada with the theme of New Scientific Developments in Biotechnology of Modern Era.

Track 1:Biochemistry & Molecular Biotechnology

Molecular biotechnology is the use of laboratory techniques to study and modify nucleic acids and proteins for applications in areas such as human and animal health, agriculture, and the environment. Molecular biotechnology results from the convergence of many areas of research, such as molecular biology, microbiology, biochemistry, immunology, genetics, and cell biology. It is an exciting field fueled by the ability to transfer genetic information between organisms with the goal of understanding important biological processes or creating a useful product.

The key drivers for molecular biology enzymes, kits and reagents market are the rising R&D expenditure by the pharmaceutical and biotech companies, and increasing public funding for life science research. The World Health Organization estimates that the total aged population may rise from 605 million in 2000 (11% of the global population) to 2 billion by 2050, accounting for 22% of the global population.

Track 2:Animal biotechnology

It improves the food we eat - meat, milk and eggs. Biotechnology can improve an animals impact on the environment. Animal biotechnology is the use of science and engineering to modify living organisms. The goal is to make products, to improve animals and to develop microorganisms for specific agricultural uses. It enhances the ability to detect, treat and prevent diseases, include creating transgenic animals (animals with one or more genes introduced by human intervention), using gene knock out technology to make animals with a specific inactivated gene and producing nearly identical animals by somatic cell nuclear transfer (or cloning).

Track 3:Biomedicine Engineering

Medicine is by means of biotechnology techniques so much in diagnosing and treating dissimilar diseases. It also gives opportunity for the population to defend themselves from hazardous diseases. The pasture of biotechnology, genetic engineering, has introduced techniques like gene therapy, recombinant DNA technology and polymerase chain retort which employ genes and DNA molecules to make a diagnosis diseases and put in new and strong genes in the body which put back the injured cells. There are some applications of biotechnology which are live their part in the turf of medicine and giving good results.

This field seeks to close the gap between engineering and medicine. It combines the design and problem solving skills of engineering with medical and biological sciences to advance health care treatment, including diagnosis, monitoring and therapy. Prominent biomedical engineering applications include the development of biocompatibleprostheses, various diagnostic and therapeutic medical devices ranging from clinical equipment to micro-implants, common imaging equipment such as MRIs and EEGs, regenerative tissue growth, pharmaceutical drugs and therapeutic biological.

Track 4:Agricultural Biotechnology

Biotechnology is being used to address problems in all areas of agricultural production and processing. This includes plant breeding to raise and stabilize yields; to improve resistance to pests, diseases and abiotic stresses such as drought and cold; and to enhance the nutritional content of foods. Modern agricultural biotechnology improves crops in more targeted ways. The best known technique is genetic modification, but the term agricultural biotechnology (or green biotechnology) also covers such techniques as Marker Assisted Breeding, which increases the effectiveness of conventional breeding.

Track 5:Food Processing & Technology

Food processing is a process by which non-palatable and easily perishable raw materials are converted to edible and potable foods and beverages, which have a longer shelf life. Biotechnology helps in improving the edibility, texture, and storage of the food; in preventing the attack of the food, mainly dairy, by the virus like bacteriophage producing antimicrobial effect to destroy the unwanted microorganisms in food that cause toxicity to prevent the formation and degradation of other toxins and anti-nutritional elements present naturally in food.

Track 6:Industrial Biotechnology

Industrial biotechnology is the application of biotechnology for industrial purposes, including industrial fermentation. The practice of using cells such as micro-organisms, or components of cells like enzymes, to generate industrially useful products in sectors such as chemicals, food and feed, detergents, paper and pulp, textiles and biofuels. Industrial Biotechnologyoffers a premier forum bridging basic research and R&D with later-stage commercialization for sustainable bio based industrial and environmental applications.

Track 7: Pharmaceutical Biotechnology

Pharmaceutical Biotechnology is the science that covers all technologies required for producing, manufacturing and registration of biological drugs.Pharmaceutical Biotechnologyis an increasingly important area of science and technology. It contributes in design and delivery of new therapeutic drugs,diagnosticagents for medical tests, and in gene therapy for correcting the medical symptoms of hereditary diseases. The Pharmaceutical Biotechnology is widely spread, ranging from many ethical issues to changes inhealthcarepractices and a significant contribution to the development of national economy.Biopharmaceuticalsconsists of large biological molecules which areproteins. They target the underlying mechanisms and pathways of a disease or ailment; it is a relatively young industry. They can deal with targets in humans that are not accessible with traditional medicines.

Track 8:Environmental biotechnology

Biotechnology is applied and used to study the natural environment. Environmental biotechnology could also imply that one tries to harness biological process for commercial uses and exploitation. The development, use and regulation of biological systems for remediation of contaminated environments and for environment-friendly processes (green manufacturing technologies and sustainable development). Environmental biotechnology can simply be described as "the optimal use of nature, in the form of plants, animals, bacteria, fungi and algae, to produce renewable energy, food, and nutrients in a synergistically integrated cycle of profit making processes where the waste of each process becomes the feedstock for another process".

Track 9:Genetic & Tissue Engineering

One kind of biotechnology is gene technology, sometimes called 'genetic engineering' or 'genetic modification', where the genetic material of living things is deliberately altered to enhance or remove a particular trait and allow the organism to perform new functions. Genes within a species can be modified, or genes can be moved from one species to another.

Tissue engineering is emerging as a significant potential alternative or complementary solution, whereby tissue and organ failure is addressed by implanting natural, synthetic, or semisynthetic tissue and organ mimics that are fully functional from the start or that grow into the required functionality. Initial efforts have focused on skin equivalents for treating burns, but an increasing number of tissue types are now being engineered, as well as biomaterials and scaffolds used as delivery systems. A variety of approaches are used to coax differentiated or undifferentiated cells, such as stem cells, into the desired cell type. Notable results include tissue-engineered bone, blood vessels, liver, muscle, and even nerve conduits. As a result of the medical and market potential, there is significant academic and corporate interest in this technology.

Track 10:Nano Biotechnology

Nano biotechnology, bio nanotechnology, and Nano biology are terms that refer to the intersection of nanotechnology and biology. Bio nanotechnology and Nano biotechnology serve as blanket terms for various related technologies. The most important objectives that are frequently found in Nano biology involve applying Nano tools to relevant medical/biological problems and refining these applications. Developing new tools, such as peptide Nano sheets, for medical and biological purposes is another primary objective in nanotechnology.

Track 11:Bioinformatics

Bioinformatics is the application of computer technology to the management of biological information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied to gene-based drug discovery and development. The science of Bioinformatics, which is the melding of molecular biology with computer science, is essential to the use of genomic information in understanding human diseases and in the identification of new molecular targets for drug discovery.

Track 12:Biotechnology investments and Biotechnology Grants

Every new business needs some startup capital, for research, product development and production, permits and licensing and other overhead costs, in addition to what is needed to pay your staff, if you have any.Biotechnology products arise from successful biotech companies. These companies are built by talented individuals in possession of a scientific breakthrough that is translated into a product or service idea, which is ultimately brought into commercialization. At the heart of this effort is the biotech entrepreneur, who forms the company with a vision they believe will benefit the lives and health of countless individuals. Entrepreneurs start biotechnology companies for various reasons, but creating revolutionary products and tools that impact the lives of potentially millions of people are one of the fundamental reasons why all entrepreneurs start biotechnology companies.

More:
Biotechnology 2017 | Biotechnology Congress | Canada ...

Read More...

Arthritis Disease Reference Guide – Drugs.com

March 20th, 2017 12:44 am

Overview

Arthritis is inflammation of one or more of your joints. The main symptoms of arthritis are joint pain and stiffness, which typically worsen with age. The most common types of arthritis are osteoarthritis and rheumatoid arthritis.

Osteoarthritis causes cartilage the hard, slippery tissue that covers the ends of bones where they form a joint to break down. Rheumatoid arthritis is an autoimmune disorder that first targets the lining of joints (synovium).

Uric acid crystals, infections or underlying disease, such as psoriasis or lupus, can cause other types of arthritis.

Treatments vary depending on the type of arthritis. The main goals of arthritis treatments are to reduce symptoms and improve quality of life.

Osteoarthritis, the most common form of arthritis, involves the wearing away of the cartilage that caps the bones in your joints. With rheumatoid arthritis, the synovial membrane that protects and lubricates joints becomes inflamed, causing pain and swelling. Joint erosion may follow.

The most common signs and symptoms of arthritis involve the joints. Depending on the type of arthritis you have, your signs and symptoms may include:

The two main types of arthritis osteoarthritis and rheumatoid arthritis damage joints in different ways.

The most common type of arthritis, osteoarthritis involves wear-and-tear damage to your joint's cartilage the hard, slick coating on the ends of bones. Enough damage can result in bone grinding directly on bone, which causes pain and restricted movement. This wear and tear can occur over many years, or it can be hastened by a joint injury or infection.

In rheumatoid arthritis, the body's immune system attacks the lining of the joint capsule, a tough membrane that encloses all the joint parts. This lining, known as the synovial membrane, becomes inflamed and swollen. The disease process can eventually destroy cartilage and bone within the joint.

Risk factors for arthritis include:

Severe arthritis, particularly if it affects your hands or arms, can make it difficult for you to do daily tasks. Arthritis of weight-bearing joints can keep you from walking comfortably or sitting up straight. In some cases, joints may become twisted and deformed.

During the physical exam, your doctor will check your joints for swelling, redness and warmth. He or she will also want to see how well you can move your joints. Depending on the type of arthritis suspected, your doctor may suggest some of the following tests.

The analysis of different types of body fluids can help pinpoint the type of arthritis you may have. Fluids commonly analyzed include blood, urine and joint fluid. To obtain a sample of your joint fluid, your doctor will cleanse and numb the area before inserting a needle in your joint space to withdraw some fluid (aspiration).

These types of tests can detect problems within your joint that may be causing your symptoms. Examples include:

Arthritis treatment focuses on relieving symptoms and improving joint function. You may need to try several different treatments, or combinations of treatments, before you determine what works best for you.

The medications used to treat arthritis vary depending on the type of arthritis. Commonly used arthritis medications include:

Physical therapy can be helpful for some types of arthritis. Exercises can improve range of motion and strengthen the muscles surrounding joints. In some cases, splints or braces may be warranted.

If conservative measures don't help, your doctor may suggest surgery, such as:

Many people use alternative remedies for arthritis, but there is little reliable evidence to support the use of many of these products. The most promising alternative remedies for arthritis include:

While you might first discuss your symptoms with your family doctor, he or she may refer you to a doctor who specializes in the treatment of joint problems (rheumatologist) for further evaluation.

Before your appointment, make a list that includes:

Your doctor is likely to ask questions, such as:

In many cases, arthritis symptoms can be reduced with the following measures:

Last updated: January 7th, 2016

1998-2017 Mayo Foundation for Medical Education and Research (MFMER). All rights reserved. Terms of use

Read more here:
Arthritis Disease Reference Guide - Drugs.com

Read More...

Promise in rheumatoid arthritis treatments – SBS

March 20th, 2017 12:44 am

A new class of drugs is offering promise for Australians living with rheumatoid arthritis.

But it's essential that the progressive and often painful immune disease is detected early, say a group of Australian experts.

RA is one of the most common forms of arthritis that affects an estimated two per cent of the Australian population.

The autoimmune disease causes the immune system to mistakenly target the body's joints.

This causes the lining of the joints to become inflamed, leading to pain, stiffness and often misalignment of the joints in the hands and feet.

As the disease progresses, symptoms often spread to the wrists, knees, ankles, elbows, hips and shoulders.

The cause of RA remains unknown and there is no cure.

Currently most patients manage the symptoms of the disease through a combination of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, and immunosuppressants.

Immunosuppressants target the whole immune system to slow the progression of RA.

However in recent years a new class of treatments known as biologics, developed through genetic engineering, have been developed.

As a result Australians with RA have "much to look forward to", say the authors of a new report in the Medical Journal of Australia - led by Professor Graeme Jones from the Menzies Institute for Medical Research at the University of Tasmania.

"There are now eight approved biological disease-modifying antirheumatic drugs (bDMARDs), two biosimilars and one targeted synthetic DMARD in Australia with a number of new products andbiosimilars in the pipeline," they wrote.

Rather than targeting the whole immune system, biologics only target and suppress elements of the body's inflammatory response that are specific to RA.

The goal is to slow down the progression of the arthritis and and preserve joint function for as long as possible.

However these therapies are most effective in the first six months of the disease.

"This means that RA should be diagnosed and treated with DMARD therapy as quickly as possible to maximise this benefit, says Prof Jones and his co-authors.

Symptoms of rheumatoid arthritis include:

- Tender, warm, swollen joints

- Morning stiffness that may last for hours

- Firm bumps of tissue under the skin on your arms (rheumatoid nodules)

- Fatigue, fever and weight loss

Follow this link:
Promise in rheumatoid arthritis treatments - SBS

Read More...

Stem cell therapy helps patients with osteoarthritis – Palm Beach Post – Palm Beach Post

March 20th, 2017 12:43 am

New treatments and advances in research are giving new hope to people affected by Osteoarthritis pain and symptoms. Dr. Theofilos provides stem cell therapy for osteoarthritis to help those achieve better health and live life in motion.

Stem cell therapy for osteoarthritis is being studied for efficacy in improving the complications in patients through the use of their own stem cells. These procedures may help patients who dont respond to typical drug treatment, want to reduce their reliance on medication, or are looking to try stem cell therapy due to pain or discomfort.

Osteoarthritis, also known as degenerative arthritis or degenerative joint disease, is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Symptoms may include joint pain, tenderness, stiffness, locking and sometimes an effusion. When bone surfaces become less well protected by cartilage, bone may be exposed and damaged. As a result of decreased movement secondary to pain, regional muscles may atrophy, and ligaments may be affected.

Stem cell treatment is designed to target these areas within the joints to help with the creation of new cartilage cells. Mesenchymal stem cells are multipotent and have the ability to differentiate into cartilage called (chondrytes). The goal of each stem cell treatment is to inject the stem cells into the joint to create cartilage.

Its expected that results of the therapy will vary depending upon the many factors of the severity, patients overall health, nutritional state and immune function. Stem cell therapy is safe and effective in reducing pain and improving function for many patients.

Voted as one of America's Top Surgeons, Charles S. Theofilos, MD, Neurosurgeon and Founder of The Spine Center is a leading provider of the state-of-the-art, most comfortable and effective surgical, minimally invasive and non-surgical treatment options for a full range of cervical and spinal ailments, including stem cell therapy and artificial disc replacement. He was among a field of 20 top neuro and orthopedic surgeons in the U.S. chosen to participate in the groundbreaking Artificial Disc Study, which compared the clinical outcome of disc replacement versus traditional spinal fusion. A widely sought after educator and lecturer, Dr. Theofilos has offices in Palm Beach Gardens and Port St. Lucie.

_______________________________________________________________

11621 Kew Gardens Ave., Suite 101; Palm Beach Gardens

*In an effort to maintain and honor the commitment to our patients, we will continue to accept Medicare and Medicare Advantage insurance plans for all new and follow up appointments.

Go here to read the rest:
Stem cell therapy helps patients with osteoarthritis - Palm Beach Post - Palm Beach Post

Read More...

Battle for sight: St. Clair’s Davidson bounces back from bout with blindness – Port Huron Times Herald

March 19th, 2017 6:44 am

St. Clair's Ben Davidson goes for a layup surrounded by Lake Shore defenders during a basketball game Tuesday, Jan. 31, 2017 at St. Clair High School.(Photo: JEFFREY M. SMITH, TIMES HERALD)Buy Photo

Ben Davidson has never been afraid of a challenge.

When he arrived at St. Clair High School, he didn't shy away from taking on a leadership role on the boys varsity basketball team. Now a junior, he has worked himself into being one of the best athletes in the Blue Water Area.

But recently Davidson faced a challenge that might just be the most difficult one he has faced in his life. And after having gone through a trying three week period, in which he was basically blind for four days, Davidson and his parents Diane and Jon have a totally different perspective on life.

"It was one of the most frightening things of my life," Ben's mother Diane Trout-Davidson said. "To see your kid scared and you are trying not to be scared."

St. Clair's Ben Davidson takes a shot during a basketball game Friday, Dec. 9, 2016 at St. Clair High School.(Photo: JEFFREY M. SMITH, TIMES HERALD)

The entire ordeal started late in the Saints boys season. Ben had been fighting what appeared to be the fluwhen he woke up feeling far different than ever before.

"I got really sick with the flu and it was bothering me," he recalled. "I had congestion problems. I just thought I was really sick and that day I woke up and I couldn't see. Light really bothered me and it was really hard to open my eyes and see. But it was a game day so I tried to go to school. I went and the first hour I couldn't do anything. I went to the office and they took me to an emergency eye wash station and tried to wash out my eyes.

"I couldn't play in the game that day and I went to Mercy Hospital in Detroit to see a special ophthalmologist. They told me I had ulcers in my eye andscratches on my corneas. I had two in my left eye and one in my right eye. They actually said they had never seen that before."

The diagnosis was just the beginning of what would be a grueling process the next several days. Davidson's parents helped treat Ben on an hourly basis and fought through fatigue to care for their son, applying eye drops every hour.

"It got really scary," Diane said. "He was in so much pain and light hurt his eyes. Your mind goes to dark places. What if he doesn't get his sight all of the way back? We were lucky. We took care of it and went to the doctor five days in a row. The first few days he wasn't getting better. But finally last Thursday he was 100 percent healed. I think this has impacted him from the little he has shared with me.

"It really scared him. So many kids think they are indestructible and he realized how lucky he is. I try to find some good in it. We spent a lot of time together as a family. We had to wake him up every hour to put antibiotics eye drops in his eyes. He said to me last week 'I really appreciate what you did for me. I know it was really hard for you.' When you said that, it was all worthwhile."

Jon, Ben and Diane Davidson at Parent night this season.(Photo: Submitted photo)

As Davidson improved, he was able to return to the court. But he wasn't the same. He played in the Saints final few games and recorded his lowest-scoring outputs of the season.

"During the two district games I was probably at 50 or 60 percent," Ben said. "It was hard. It was frustrating. I wasn't able to play up to my potential. I just tried to bring anything I could bring. It was blurry and a lot of times when I was passing the ball, I was just looking for the blue jersey. Irealized that life had more than just basketball at that moment.

"I couldn't see for four days. I couldn't open my eyes other than to put drops in them. It made me think life is more than basketball.I realized you have to be thankful to have eyesight. Those four days were the most miserable of my life. My eyes were killing me. If I opened my eyes they were blood red. It was scary. I was scared I would never see again. After four days I could see with sunglasses on."

After the season concluded and Ben reflected back on the situation, his parents said they started to see subtle changes in him.

"My wife and I noticed how thankful he was," Jon Davidson said. "He would tell us thank you 20 times, and you don't normally get that out of a teenage boy. Every hour for two days we put drops in his eyes and then every two hours and every three hours and so forth. I appreciate that he was willing to have the drive to compete even though he wasn't 100 percent. He's been like that since he was a little kid.

"I hope he takes away from this not to take anything for granted. You never know what is going to happen."

St. Clair's Ben Davidson runs the ball during a football game Friday, September 30, 2016 at East China Stadium.(Photo: JEFFREY M. SMITH, TIMES HERALD)

With the off-season officially underway, Ben is back in the gym working out for his final year of high school athletics. He said he is more motivated than ever before failing to finish the season as strong as he had hoped.

"I was giving it my all but it wasnt there," Ben said. "I wasnt proud of my play at the end of the year. It was irritating to me. A lot of people at the New Haven game thought I was overrated and talked about too much. I want to show them I can play great basketball. I think hard times make me better.

"Anything that puts me through adversity. I still think about it every day that I couldnt give 100 percent of what I had in the district, especially in the New Haven game. I was embarrassed with myself. I have to keep working. Even though the season is over I'm in the gym every day. I'm not going to be able to play together. But I want to be the best I can be."

Contact Joseph Hayes at (810) 989-6268 or at jahayes@gannett.com. Follow him on Twitter @Joseph_Hayes11.

View post:
Battle for sight: St. Clair's Davidson bounces back from bout with blindness - Port Huron Times Herald

Read More...

iShares Nasdaq Biotechnology (IBB) Crosses Into Overbought Range – Business Review

March 19th, 2017 6:44 am

Checking on current RSI levels on shares of iShares Nasdaq Biotechnology (IBB), the 14-day RSI is currently standing at 70.50, pushing the stock into overbought territory. RSI is a momentum oscillator that moves in a range from 0 to 100. RSI is generally used to interpret whether a stock is overbought or oversold. With iShares Nasdaq Biotechnologys RSI above 70, traders should be wary of a potential pullback. Looking a bit closer at other RSI timeframes we can see the 7-day RSI is at75.84 and the 3-day is at81.54.

Fundamental Data Now well take a look at how the fundamentals are stacking up for Avalon Minerals Ltd (AVI.AX). Fundamental analysis takes into consideration market, industry and stock conditions to help determine if the shares are correctly valued. Avalon Minerals Ltd currently has a yearly EPS of -0.01. This number is derived from the total net income divided by shares outstanding. In other words, EPS reveals how profitable a company is on a share owner basis.

Another ratio we can look at is the Return on Invested Capital or more commonly referred to as ROIC. Avalon Minerals Ltd (AVI.AX) has a current ROIC of -8.06. ROIC is calculated by dividing Net Income Dividends by Total Capital Invested.

Similar to ROE, ROIC measures how effectively company management is using invested capital to generate company income. A high ROIC number typically reflects positively on company management while a low number typically reflects the opposite.

Another key indicator that can help investors determine if a stock might be a quality investment is the Return on Equity or ROE. Avalon Minerals Ltd (AVI.AX) currently has Return on Equity of -8.06. ROE is a ratio that measures profits generated from the investments received from shareholders.

In other words, the ratio reveals how effective the firm is at turning shareholder investment into company profits. A company with high ROE typically reflects well on management and how well a company is run at a high level. A firm with a lower ROE might encourage potential investors to dig further to see why profits arent being generated from shareholder money.

Turning to Return on Assets or ROA, Avalon Minerals Ltd (AVI.AX) has a current ROA of -7.96. This is a profitability ratio that measures net income generated from total company assets during a given period. This ratio reveals how quick a company can turn its assets into profits. In other words, the ratio provides insight into the profitability of a firms assets. The ratio is calculated by dividing total net income by the average total assets.

A higher ROA compared to peers in the same industry, would suggest that company management is able to effectively generate profits from their assets. Similar to the other ratios, a lower number might raise red flags about managements ability when compared to other companies in a similar sector.

Go here to read the rest:
iShares Nasdaq Biotechnology (IBB) Crosses Into Overbought Range - Business Review

Read More...

Regenerative Stem Cell Treatment Offers Hope for People with … – Healthline

March 19th, 2017 6:42 am

A phase II stem cell treatment is the talk of the rheumatology community.

Stem cell treatments have been a topic of conversation among many people with autoimmune and degenerative forms of arthritis.

Now, an Australian pharmaceutical company is trying to figure out if this type of regenerative medicine could play a key role in treating or managing rheumatic diseases like rheumatoid arthritis (RA).

Mesoblast has developed a stem cell therapy that is administered intravenously to people with RA who didnt experience success taking anti-TNF drugs like Remicade, Enbrel, and Humira.

Read more: Stem cell therapy possible treatment for rheumatoid arthritis

The phase II study followed 48 patients who received one injection of the stem cell therapy.

These patients received therapeutic benefits as long as nine months after the initial dosing, company officials reported.

While more studies will be conducted in a phase III trial in order to validate the results, the results could mean positive things for the many people with RA who dont fare well on TNF-inhibitors.

Anti-TNF drugs are a billion dollar industry as well as a source of relief for many people with RA.

However, 20 to 40 percent of people treated with these medications either have an adverse reaction, or find no relief.

Perhaps the best news for people with RA who are sensitive to medications or experience pharmacophobia is that unlike some other treatments, little toxicity or side effects were indicated in the studies of Mesoblasts stem cell treatment.

Read more: Green tea for rheumatoid arthritis

The treatment uses mesenchymal precursor cells (MCPs).

Because the immune system doesnt recognize these MCPs as foreign or invaders, they dont tend to produce a negative response.

The MCP cells are adult stem cells, not embryonic stem cells.

The cells work because they contain certain receptors targeting the RA response and altering the way the bodys immune system works or, in the sense of RA, the way it malfunctions.

According to a published statement to the press from Mesoblast, The way the cells work is, they have receptors on their surface that are activated by every major cytokine that is important in progressive rheumatoid arthritis, including TNF, IL-1, IL-6, IL-17. Those cytokines drive the disease and also bind to receptors on our cells. And when they bind to our cells they activate the cells to release other factors that switch off the very cells that made those cytokines.

There continues to be more research done on stem cell therapy as a way to treat immune, autoimmune, and inflammatory diseases.

In the United States, a company called Regenexx shares some stem cell success stories on their website, often pertaining to healing osteoarthritis or injury.

While in the past, stem cells were only used to treat orthopedic injuries and conditions, newer research like the targeted regenerative stem cell therapy that is being created by Mesoblast also aims to treat other forms of arthritis like RA.

Read more: Biologic treatments for rheumatoid arthritis

Follow this link:
Regenerative Stem Cell Treatment Offers Hope for People with ... - Healthline

Read More...

American Academy of Ophthalmology Statement on Stem Cell Therapy for Treating Eye Disease – PR Newswire (press release)

March 19th, 2017 6:42 am
American Academy of Ophthalmology Statement on Stem Cell Therapy for Treating Eye Disease
PR Newswire (press release)
The Academy has previously issued clinical guidance that covers the appropriate use of stem cell therapy in eye care. These recent cases confirm the Academy's belief that the FDA should thoroughly investigate and level regulatory action against ...

See the article here:
American Academy of Ophthalmology Statement on Stem Cell Therapy for Treating Eye Disease - PR Newswire (press release)

Read More...

Vision 20/20: New nano-implant may help restore eyesight – Hindustan Times

March 18th, 2017 3:45 am

The technology could help people worldwide suffering from neurodegenerative diseases that affect eyesight, including macular degeneration, retinitis pigmentosa and loss of vision due to diabetes.

Scientists have developed a new eye implant, using arrays of silicon nanowires that sense light and electrically stimulate the retina, which may help restore vision in millions of people worldwide.

The advance brings us a step closer to restoring the ability of neurons in the retina to respond to light.

The researchers from University of California San Diego and US-based startup Nanovision Biosciences showed response to light in a rat retina interfacing with a prototype of the device in vitro.

The technology could help tens of millions of people worldwide suffering from neurodegenerative diseases that affect eyesight, including macular degeneration, retinitis pigmentosa and loss of vision due to diabetes.

Performance of current retinal prostheses to help the blind regain functional vision is still limited.

We want to create a new class of devices with drastically improved capabilities to help people with impaired vision, said Gabriel A Silva, professor at UC San Diego.

Performance of current retinal prostheses to help the blind regain functional vision is still limited. (Shutterstock)

The new prosthesis relies on two groundbreaking technologies. One consists of arrays of silicon nanowires that simultaneously sense light and electrically stimulate the retina accordingly.

The nanowires give the prosthesis higher resolution than anything achieved by other devices closer to the dense spacing of photoreceptors in the human retina. The other breakthrough is a wireless device that can transmit power and data to the nanowires over the same wireless link at record speed and energy efficiency.

The new system does not require a vision sensor outside of the eye to capture a visual scene and then transform it into alternating signals to sequentially stimulate retinal neurons. Instead, silicon nanowires mimic the light-sensing cones and rods to directly stimulate retinal cells.

Nanowires are bundled into a grid of electrodes, activated by light and powered by a single wireless electrical signal. This direct and local translation of incident light into electrical stimulation makes for a much simpler and scalable architecture for the prosthesis.

To restore functional vision, it is critical that the neural interface matches the resolution and sensitivity of the human retina, said Gert Cauwenberghs, from UC San Diego.

Read more

Power is delivered wirelessly, from outside the body to the implant, through an inductive powering telemetry system. For proof-of-concept, the researchers inserted the wirelessly powered nanowire array beneath a transgenic rat retina with rhodopsin P23H knock-in retinal degeneration.

The degenerated retina interfaced with a microelectrode array for recording electrical spikes from neural activity. The horizontal and bipolar neurons fired action potentials preferentially when the prosthesis was exposed to a combination of light and electrical potential and were silent when either light or electrical bias was absent, confirming the light-activated and voltage-controlled responsivity of the nanowire array.

The research was published in the Journal of Neural Engineering.

Follow @htlifeandstyle for more.

Read the original here:
Vision 20/20: New nano-implant may help restore eyesight - Hindustan Times

Read More...

Page 1,079«..1020..1,0781,0791,0801,081..1,0901,100..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick